The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips

European Journal of Pharmacology

Volumn 462, Issue 1-3, 2003, Pages 155-160

  Kilicarslan, Hakan ^a   Yildirim, Sahin ^a   Bagcivan, Ihsan ^a   Gokce, Gokhan ^a   Sarac, Bulent ^a   Sarioglu, Yusuf ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

(Rabbit); Impotence; Phosphodiesterase inhibitor; Renal failure

Indexed keywords

AMRINONE; PAPAVERINE; PHENYLEPHRINE; SILDENAFIL; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFICACY; MALE; NEPHRECTOMY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RABBIT; SURGICAL TECHNIQUE; UREMIA;

EID: 12244310148     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01296-2     Document Type: Article

References (31)

1. Andersson K.E., Wagner G. Physiology of penile erection. Physiol. Rev. 75:1995;191-236.
2. Azadzoi K.M., Kim N., Brown M.L., Goldstein I., Cohen R.A., Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J. Urol. 147:1992;220-225.
3. Bagcivan I., Kilicarslan H., Sarac B., Gokce G., Yildirim S., Ayan S., Sarioglu Y. The evaluation of the effects of renal failure on erectile dysfunction in a chronic renal failure (CRF) rabbit model. BJU Int. 2003;. (in press).
4. Ballard S.A., Gingell C.J., Tank G., Turner L.A., Price M.E., Naylor A.M. Effects on sildenafil the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159:1998;2164-2171.
5. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
6. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell J.C. Sildenafil an orally active type 5 cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 8:1996;47-52.
7. Boolell M., Gepi-Attee S., Gingell J.C., Allen M.J. Sildenafil a novel oral therapy for male erectile dysfunction. Br. J. Urol. 78:1996;257-261.
8. Bush P.A., Aronson W.J., Buga G.M., Rajfer J., Ignarro L.J. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J. Urol. 147:1992;1650-1655.
9. Campese V.M., Liu C.L. Sexual dysfunction in uremia. Endocrine and neurological alterations. Contrib. Nephrol. 77:1990;1.
10. Glass C.A., Fielding D.M., Evans C., Ashcroft J.B. Factors related to sexual functioning in male patients undergoing hemodialysis and with kidney transplants. Arch. Sex. Behav. 16:1987;189.
11. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. New Engl. J. Med. 338:1998;1397-1404.
12. Gotloib L., Crassweller P., Rodella H., Oreopoulos D.G., Zellerman G., Ogilvie R., Husdan H., Brandes L., Vas S. Experimental model for studies of continuous peritoneal dialysis in uremic rabbits. Nephron. 31:1982;254-259.
13. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cAMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. 79:1997;958-963.
14. Jünemann K.P., Persson-Jünemann C., Alken P. Pathophysiology of erectile dysfunction. Semin. Urol. 8:1990;80.
15. Karacan I., Dervent A., Cunningham G., Moore C.A., Weinman E.J., Cleveland S.E., Salis P.A., Williams R.L., Kopel K. Assessment of nocturnal penile tumescence as an objective method for evaluating sexual functioning in ESRD patients. Dial. Transplant. 7:1978;872.
16. Lincoln T.M. Cyclic GMP and mechanisms of vasodilatation. Pharmacol. Ther. 41:1989;479-502.
17. Lue T.F., Tanagho E.A. Physiology of erection and pharmacological management of impotence. J. Urol. 137:1987;829-836.
18. Medina P., Segarra G., Martinez-Leon J.B., Vila J.M., Aldasoro M., Otero E., Lluch S. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann. Thorac. Surg. 70:2000;1327-1331.
19. Oreopoulos A.K., Balaskas E.V., Rodela H., Anderson G.H., Oreopoulos D.G. An animal model for the study of amino acid metabolism in uremia and during peritoneal dialysis. Perit. Dial. Int. 13:1992;499-507.
20. Palmer B.F. Sexual dysfunction in uremia. J. Am. Soc. Nephrol. 10:1999;1381.
21. Procci W.R., Goldstein D.A., Adelstein J., Massry S.G. Sexual dysfunction in the male patient with uremia: a reappraisal. Kidney Int. 19:1981;317.
22. Rajfer J., Aronson W.J., Bush P.A., Dorey F.J., Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. New Engl. J. Med. 326:1992;90-92.
23. Rodger R.S., Fletcher K., Dewar J.H., Genner D., McHugh M., Wilkinson R., Ward M.K., Kerr D.N. Prevalence and pathogenesis of impotence in one hundred uremic men. Uremia Invest. 8:1984;89.
24. Schoeffier P., Stoclet J. Effects of vasoactive intestinal polypeptide (VIP) on cyclic AMP level and relaxation in rat isolated aorta. Eur. J. Pharmacol. 109:1985;275-279.
25. Sparwasser C., Drescher P., Will J.A., Madsen P.O. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP and cyclic GMP dependent mechanisms. J. Urol. 152:1994;2159-2163.
26. Stief C.G., Uckert S., Becker A.J., Truss M.J., Jonas U. The effect of the specific phosphodiesterase inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J. Urol. 159:1998;1390-1393.
27. Taher A., Meyer M., Stief C.G., Jonas U., Forssmann W.G. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J. Urol. 15:1997;32-35.
28. Thompson W.J. Cyclic nucleotide phosphodiesterases pharmacology, biochemistry and function. Pharmacol. Ther. 51:1991;13-33.
29. Trigo-Rocha F., Aronson V.J., Hohenfellner M., Ignarro L.J., Rajfer J., Lue T.F. Nitric oxide and cGMP mediators of pelvic nerve-stimulated erection in dogs. Am. J. Physiol. 264:1993;419-422.
30. Truss M., Becker A.Z., Schultheiss D., Jonas U. Intracavernous pharmacotherapy. World J. Urol. 15:1997;71-77.
31. Willis E., Ottesen B., Wagner G., Sundler F., Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection. Acta. Physiol. Scand. 113:1981;545-547.